Key takeaways
Indacaterol (Arcapta Neohaler) and formoterol (Perforomist) are both long-acting beta-agonists (LABAs) used to treat chronic obstructive pulmonary disease (COPD). However, they have several differences. Indacaterol was available as an inhaler but has been discontinued and is no longer available in the U.S., while formoterol is available by prescription and requires a nebulizer for administration. Formoterol is typically dosed at 20 micrograms twice daily using a nebulizer. Common side effects of formoterol include diarrhea, nausea, and dizziness, and it should not be used for asthma or sudden breathing problems. Additionally, using formoterol with albuterol may increase the risk of heart-related side effects.
